Darovasertib not checked
IDEAYA Biosciences · LXS196 · IDE196
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Uveal Melanoma (3 trials), Metastatic Uveal Melanoma (2 trials), Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Main trialPhase 3
- “This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)”In the company’s words, NCT07015190 on ClinicalTrials.gov
- Other names
- LXS196 · IDE196
Other drugs for Uveal Melanoma
- AU-011Aura Biosciences · Phase 3
- RP2Replimune, Inc. · Phase 2/3
- Melphalan/HDSDelcath Systems Inc. · Phase 3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- DYP688Novartis Pharmaceuticals · Phase 1/2
- RoginolisibiOnctura · Phase 2
Coming up5
- 15 Jan 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 29 Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2030Phase 3 trial completes · ClinicalTrials.gov
- Mar 2034Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2030 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | |
| Phase 3Recruiting | Mar 2034 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | |
| Phase 2/3Active, not recruiting | 15 Jan 2027 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | |
| Phase 2Active, not recruiting | 30 Apr 2027 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | |
| Phase 1/2Recruiting | 29 Jan 2027 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | |
| Phase 1Terminated | 7 Jan 2022 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026